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Summary Sexual function can be altered in patients with different types o
epileptic disorder, especially those with temporal lobe epilepsy. The awareness o
sexual function disturbances, giving an enormous impact on someone’s quality of life
should lead to therapeutic measures. The incidence, evaluation and therapeutic
options are demonstrated and seen through the urologist’s eyes.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Disturbances in sexuality signify a major limitation
in quality of life and may have harmful effects on
nearly all areas of life in those affected by these
conditions, which is a very important indicator of
the patients health status.1,2 Epidemiological stu-
dies showed that the overall prevalence of erectile
dysfunction in men in the general population world-
wide is approximately 20—22%, which means that
sexual problems have much more impact on public
health status than usually assumed.3—6
The leading sexual function disorders in men
include reduction of libido, erectile dysfunction
as well as orgasm and ejaculation disorders. In more
than 60% of men who complain about erectile dys-
function organic reasons, especially endothelial and
metabolic dysfunction like hypertension, coronary
heart disease, hypercholesterolemia and diabetes
mellitus3,2,6 underlie the symptoms. In men, some
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tract symptoms) are frequently accompanied by
erectile dysfunction and the necessary operative
therapy will by itself lead to sexual dysfunction in
4—10% of the patients.6,7
Other reasons for developing sexual dysfunction
are age, life-style, alcohol- and nicotine-abuse,
obesity and drug-induced side effects6. It is often
discussed, but not well studied yet how deep the
impact of therapeutic necessary drug intake is on
sexual function in detail.
It was clearly demonstrated that patients with
different types of neurological disorders have a
higher risk to develop sexual dysfunction than the
general population.
About 40 million people are affected with epi-
lepsy worldwide8,9 and numerous symptoms of sex-
ual disorders can be seen in patients with epilepsy.
Sexual activity itself can provoke a seizure through
hyperventilation and triggering the genital sensory
cortical area. Sexual phenomena may also be a part
of an epileptic seizure, for example motor symp-
toms such as erection, ejaculation, orgasm, pelvic
sexual movements, or compulsive masturbation.10. Published by Elsevier Ltd. All rights reserved.
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affected by sexual function disorders. Hyposexual-
ity is the predominant syndrome which is character-
ized by the loss of sexual desire, reduced sexual
activity, and inhibited sexual arousal.9,11 On the
other hand organic sexual problems are also fre-
quently seen. Especially a lack of spontaneous noc-
turnal and morning penile tumescence, orgasm
disturbances, erectile dysfunction, premature eja-
culation and fertility problems due to hypogonadism
and hyperprolactinemia with consecutively reduced
sperm quality.11,12
Studies showed that due to sexual problems,
male patients have a lower marriage rate and have
fewer children than expected.13
A correlation between hyposexuality and the
seizure severity or seizure frequency has been
described. It has been shown that longer periods
of remission are associated with lower rates of
hyposexuality. Recently published studies show that
the risk of manifested sexual dysfunction is
increased with poor seizure control and also with
depression, which is a common comorbid disorder in
epilepsy.14—16 This leads to the suggestion that ade-
quate treatment — invasive operative methods or
modern medical treatment — of epilepsy may lead
to an improvement of sexual function.5,15,17,18
It has not yet been shown clearly if the onset of
epilepsy and/or a remission prior the age of 12—14
are correlated with a better sexual performance.
Gastaut and Collomb postulated in 1954, that the
onset of seizures prior or during puberty may have a
strong effect on the hypothalamic—pituitary axis
decreasing the gonadotropin levels with consecu-
tive effects on the sexual performance and beha-
viour, but recent studies could not confirm this.17,19
The reasons for developing sexual dysfunction are
multi-factorial. Some of the symptoms are caused
by the epilepsy itself while others may be caused by
the antiepileptic medication.12,20,21 Several studies
showed that particularly men with temporal lobe
epilepsy are affected.
Epileptiform discharges from the temporal lobe
region may be transmitted through amygdala—
hypothalamic pathways, disrupting the normal pul-
satile secretion of gonadotropic hormones and the
basal levels of dopamine secretion, resulting in
hypogonadism and hyperprolactinemia that leads
to hyposexuality, lack of libido, erectile dysfunction
and reduced sperm quality.4,18—20
However, there is sufficient evidence to suggest
that particularly the strong enzyme-inducing anti-
epileptic drugs, which are metabolised in the liver,
such as carbamazepine, phenytoin, phenobarbital
or primidone, change the hormone balance of the
male organism. These substances enhance the activ-ity of the hepatic cytochrome-P450 enzyme system
and increase the formation of sexual hormone bind-
ing globulin which, in return, reduces the free
biologically active testosterone and increases the
inactive bound form. This is thought to contribute to
the sexual dysfunction observed in patients with
epilepsy who are on chronic treatments.19,22
With modern antiepileptic drugs that exert no or
only a marginal effect on the cytochrome-P450
enzyme system of the liver, this phenomenon is
more or less negligible.
This fact should be taken into account when
administering antiepileptic medication to men–—
especially if therapy is started in adolescent or
juvenile men.16,18,23Evaluation
The initial evaluation of any patient with sexual,
especially erectile dysfunction, should be done with
awareness for the multi-factorial etiologies. It is not
plausible to consider anticonvulsant medication as
the only cause of sexual dysfunction in men with
epilepsy. Besides the epilepsy itself, the prescribed
antiepileptic drugs and psychosocial components,
other organic and medication-induced factors might
be causative. Interdisciplinary diagnostic strategies
are necessary.
The initial evaluation of patients with sexual
dysfunction should therefore include a full endo-
crine and metabolic status. Serum levels of testos-
terone, estradiol and prolactin, and the thyroidal
function should be evaluated. The correction of free
testosterone level is the easiest way to regain sexual
desire and fertility disorders.
Erectile dysfunction can be the first clinical sign
of an unknown and untreated coronary heart dis-
ease, so it is important to be informed about con-
comitant diseases, especially the cardiac condition
of the patient. Furthermore, unforeseen drug—drug
interactions between the established and the
planned drugs for sexual therapy can be minimized
when the patient is well investigated and his general
practitioner is involved.
The medication history plays an important role.
Beside the antiepileptic therapy, there are many
possible drug side effects leading to sexual dysfunc-
tion, for example b-inhibiting agents, sedatives,
antidepressants and diuretics.
The clinical investigation should include the uro-
genital region, the size of the prostate and the
emptying mechanism of the bladder. There is some
evidence that treatment of bladderneck obstruction
and lower urinary tract symptoms (i.e. with alfuzo-
sin retard, anticholinergic agents) may lead to bet-
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tional index for erectile function) and the erection
hardness score helps to standardize erectile dys-
function and are useful and clinical instruments to
show success during therapy.2,24 The nocturnal
tumescence measurement is useful, but needs hos-
pitalisation over night to get correct results and is a
diagnostic tool that plays a minor role in the diag-
nosis and therapy of outpatients. It helps to distin-
guish between organic and psychogenic erectile
dysfunction: physiological erectile dysfunction
should impair daytime and nocturnal erections
equally.
Furthermore a psychological screening for
depression and anxiety disorders and a complete
evaluation of his sexual and relationship history is
necessary to understand a patient’s complaints. Life
stressors should be considered as contributing fac-
tors to sexual disturbances.Therapy
Once the etiology of sexual dysfunction is deter-
mined, proper treatment strategies should follow.
The sequential procedure should be first to treat the
epilepsy and then, if the neuroendocrine dysfunc-
tion of the patient persists, to discuss a supplemen-
tal hormonal therapy.
Modern antiepileptic treatment should — besides
seizure freedom — also include the challenge of
achieving the best conditions for sexuality and fer-
tility for the treated patient. Several studies
demonstrate that there is a remarkable benefit
for patients suffering from hyposexuality using or
switching to antiepileptic agents with no or less
enzyme-inducing effect. Thus, oxcarbazepine may
be a more effective form of treatment in patients
with epilepsy suffering from hyposexuality.23
If the erectile dysfunction is physiologically
mediated, additional pharmacologic treatment
may be necessary. The first-line therapy is erec-
tion-enhancing phophodiesterase type-5 inhibitor
drugs (sildenafil, vardenafil, tadalafil). These drugs
are safe and highly effective, but will not have any
impact on sexual desire and interest. So patient
education and follow-up appointments are essen-
tial to ensure optimal outcomes of pharmacological
treatments for sexual dysfunction. For example
McCollough et al. could show that treating erectile
dysfunction with sildenafil needs up to eight times
use of the drug to achieve the best clinical
result.25—27
Due to the metabolism of sildenafil by the cyto-
chrome-P450 liver-enzyme system a dose-adaption
for the PDE-5-inhibitors might be needed especiallyif the patient’s antiepileptic treatment is based on
enzyme-inducing agents (carbamazepine, valpro-
ate, phenytoin).
There are a few case reports28,29 of tonic-clonic
seizures following the use of PDE-5 inhibitors (2
cases with sildenafil, 1 case with vardenafil). All
the patients had no pre-existing lesion and no pre-
vious seizure-events in their history. The suggestion
is that the epileptogenic potential of the drug itself
may be causative or the seizure was provoked by its
vascular complications.29
Further therapy options for sexual function dis-
orders belong to the urologist’s armamentarium:
placing an elastic constricting band at the base of
the penis to prevent outflow of blood, using a
vacuum device and creating negative pressure
drawing blood into the cavernous body to achieve
and maintain erection. More invasive regimens, but
well effective are the intraurethral application of
prostaglandin E1, so-called MUSE, or the intracaver-
nosal self-injection of papaverine, phentolamine
and prostaglandine E1 (SKAT). The urologists nowa-
days prefer the prostaglandine E1-agents to avoid
the risk of unwanted prolonged and painful erection
(priapism).27,30
Surgical treatment, for example the implantation
of a hydraulic penis-prosthesis may be used effec-
tively in individual cases, when the therapy-strate-
gies mentioned above failed.
Often underestimated but nevertheless one of
the most important success factors of a therapy
of sexual disorders is the involvement of the
patient’s partner. An expert counselling is helpful,
and above all there is a need of minimizing impairing
co-factors (metabolic disturbances, obesity, life-
style, nicotine-abuse).
Still today, the therapeutic options for the treat-
ment of ejaculation and orgasm disorders are not
sufficient. The premature ejaculation, focus of
ongoing studies, is the next problem that will hope-
fully be solved with help of short-time selective
serotonin reuptake inhibitors that can be used in
clinical practice very soon. The therapeutic options
accessible today are non-approved, but more or less
effective: topical application of local anaesthetics
(gel, spray, cream containing lidocaine or prilo-
caine), manual pressure on sexual trigger points,
oral intake of clomipramine and SSRI-agents like
fluoxetine, paroxetine and sertaline. The suggestion
is that SSRI drugs lead to desensitization of 5-hydro-
xytryptamine receptors retarding the ejaculation
reflex. In animal studies it was demonstrated clearly
that activation of the 5-HTA1 receptors facilitates
ejaculation. It is assumed that in men these recep-
tors have similar effects, but evidence-based data
about their role in men is still lacking. Adverse
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taken on an empty stomach, loose stool or perspira-
tion. Patients may also report diminished sexual
desire and weak erections. It may be necessary to
combine SSRI and PDE-5-inhibitors to handle these
effects.31Conclusion
Sexual dysfunctions are genuine, common, rele-
vant, distressing and complicated human bio-psy-
cho-social conditions. Men with epilepsy have been
found to have an increased risk of erectile dysfunc-
tion in up to 57%. The management of sexual dis-
order must include interdisciplinary investigational
and therapeutic strategies. Besides, an internist’s
evaluation, a cardiologic and a urogenital evalua-
tion should be done because of comorbidities and
their impact on sexual performance. Hormonal dis-
turbances have to be corrected to regain sexual
desire and potency. The antiepileptic medication
can not be considered as the only reason for sexual
dysfunction in men with epilepsy, but there is a need
of avoiding long-time intake of enzyme-inducing
agents due to the consecutive hypogonadism and
hyperprolactinemia with erectile and fertility pro-
blems. Further scientific efforts should be made to
find out more clearly how prominent the role of
antiepileptic medication is in developing of sexual
dysfunction compared to the impact of the epilepsy
itself.
When treating epilepsy, one has to consider that
in addition to achieving seizure freedom, one must
pay attention to sexuality, quality of life and the
patient’s partnership as well. The urologic thera-
peutic options for sexual dysfunction in males with
epilepsy concentrate on enhancing and maintaining
erection. The use of PDE-5 inhibitors seems to be
safe and effective in men with neurological disor-
ders, but is not yet well investigated in men with
epilepsy which should be the focus of further stu-
dies. Finally, therapy of sexual disorders is more
than prescribing a pill or giving testosterone, it is
based on communication.References
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